Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Century Therapeutics, Inc.IPSC · Entity 5739 | Chief Scientific Officer | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Century Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,175,322 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Tax withholding · Disposed 358 · Balance 1,175,322 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 10,697 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,697 F2: Shares held by the Cowan Investment Nominee Trust. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
F2: Shares held by the Cowan Investment Nominee Trust. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 23:54 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 358 | $2.24 | $801.92 |
DisclosureSEC source: 0002039294-26-000010 · form4-06152026_110619.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,175,322 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 23:18 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 1,365 | $2.19 | $2,989.35 |
DisclosureSEC source: 0002039294-26-000008 · form4-04032026_110429.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,175,680 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:05 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 1,431 | $2.73 | $3,906.63 |
DisclosureSEC source: 0002039294-26-000006 · form4-03132026_080344.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,177,045 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 265,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0002039294-26-000004 · form4-02042026_090252.xml · derivative · entry 3 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2036-02-02 F3 · derivative.exercise_date: The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002039294-26-000004 · form4-02042026_090252.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,178,476 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 1,611 | $1.00 | $1,602.95 |
DisclosureSEC source: 0002039294-26-000002 · form4-01062026_090146.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,043,476 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:52 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | PurchaseCommon Stock | 58,060 | $0.85 | $49,252.30 |
DisclosureSEC source: 0002039294-25-000008 · form4-12292025_091223.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,045,087 F1 · kind: All profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:05 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 5,462 | $0.50 | $2,736.46 |
DisclosureSEC source: 0002039294-25-000006 · form4-11242025_091151.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 987,027 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:56 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 762,543 | $0.00 | $0.00 |
DisclosureSEC source: 0002039294-25-000004 · form4-09222025_080929.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 992,489 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 50% on October 1, 2026, with the remaining 50% vesting on October 1, 2027, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:31 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001062993-25-005293 · form4.xml · derivative · entry 3 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-03-11 F3 · derivative.exercise_date: The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:31 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-005293 · form4.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,306 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 22:04 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 446,250 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001062993-24-017405 · form4.xml · derivative · entry 3 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,250 Underlying: Common Stock · 446,250 shares Expires 2034-10-01 F3 · derivative.exercise_date: The option vests 25% on October 1, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 22:04 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 74,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-017405 · form4.xml · nonDerivative · entry 1 Cowan Chad · CIK 0002039294 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,806 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on October 1, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.